A Tale of Two New Hepatitis C Drugs
Despite discount, Merck’s just approved Zepatier unlikely to win share with most US payers, except in Medicaid, according to RxScorecard™. New combo from Gilead could ensure company’s dominant position among US payers. - March 11, 2016
Real Endpoints’ RxScorecard™ Predicted Launch Failure of Major New Anti-Cholesterol Drugs
Analysis from 2015 showed that because PCSK9 inhibitors had not proved more than incremental value for most patients, payers would dramatically restrict their usage. Poor Q4 sales show that’s exactly what happened. - February 12, 2016
Press Releases 1 - 2 of 2